Global biopharmaceutical firm AstraZeneca is investing $300 million in an 84,000-square-foot manufacturing facility in Rockville, MD to launch its cell therapy platforms in the U.S. for critical cancer trials and future commercial supply. Located at 9950 Medical Center Dr., it is expected to become operational in 2026.

More than 150 new highly skilled jobs will be created to initially focus on manufacturing T-cell therapies to enable clinical trials to be conducted around the world. Over time, the site may expand its focus to support other disease areas.

The Rockville facility is located less than five miles from one of the company’s five global R&D centers and sits within the life sciences corridor in Maryland. The company recently signed a full-building lease in Gaithersburg.

Maryland Gov. Wes Moore said: “AstraZeneca and the State of Maryland share a deep commitment to innovation. It makes us the perfect pairing for this next-generation cell therapy facility. This significant investment in our life sciences sector will help maintain Maryland’s leadership in the industry and sharpen our competitive edge.”

The post AstraZeneca to Expand Montgomery County Manufacturing Operations appeared first on Connect CRE.